Literature DB >> 32112307

Application of the Z1071 criteria: classification of axillary lymph nodes on ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer.

Naoko Iwamoto1, Hiromi Miyamoto2, Shinichiro Horiguchi3, Yayoi Honda2, Tomoyuki Aruga2.   

Abstract

PURPOSE: The American College of Surgeons Oncology Group (ACOSOG) Z1071 trial assessed the accuracy of sentinel lymph node biopsies in clinically node-positive patients who underwent neoadjuvant chemotherapy (NAC). Axillary ultrasound (US) images after NAC were reviewed, and the accuracy of classifying nodes into six types according to the ACOSOG Z1071 trial was determined.
METHODS: This study included 69 patients who underwent NAC followed by curative surgery for breast cancer including axillary lymph node dissection between January 2010 and July 2019. All patients were pathologically confirmed as being initially node positive. Lymph nodes were retrospectively classified into one of six types based on the appearance of the nodal cortex and hilum. Types I and II were classified as having normal nodal morphology, whereas types III, IV, V, and VI were classified as having suspicious nodal morphology. These node types on US images after NAC were compared between patients with an axillary complete response (Ax-pCR) and those with residual metastatic lymph nodes (Ax-non-pCR) using Chi-square tests.
RESULTS: Twenty-four (35%) of the 69 patients achieved Ax-pCR. Patients with nodes classified as type I or II were more likely to achieve Ax-pCR (83% vs. 36%, p = 0. 0002).
CONCLUSION: The classification of six node types was associated with nodal status.

Entities:  

Keywords:  Complete response; Cortex; Imaging

Mesh:

Year:  2020        PMID: 32112307     DOI: 10.1007/s10396-020-01010-0

Source DB:  PubMed          Journal:  J Med Ultrason (2001)        ISSN: 1346-4523            Impact factor:   1.314


  15 in total

1.  Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy.

Authors:  Hee Jun Choi; Jai Min Ryu; Isaac Kim; Seok Jin Nam; Seok Won Kim; Jonghan Yu; Jeong Eon Lee; Se Kyung Lee
Journal:  Breast Cancer Res Treat       Date:  2019-05-07       Impact factor: 4.872

2.  The use of ultrasound in the clinical re-staging of the axilla after neoadjuvant chemotherapy (NACT).

Authors:  Anastasia Peppe; Robin Wilson; Romney Pope; Kate Downey; Jennifer Rusby
Journal:  Breast       Date:  2017-07-11       Impact factor: 4.380

3.  A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Olga Kantor; Lynn McNulty Sipsy; Katharine Yao; Ted A James
Journal:  Ann Surg Oncol       Date:  2018-01-24       Impact factor: 5.344

4.  Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

Authors:  Jean-Francois Boileau; Brigitte Poirier; Mark Basik; Claire M B Holloway; Louis Gaboury; Lucas Sideris; Sarkis Meterissian; Angel Arnaout; Muriel Brackstone; David R McCready; Stephen E Karp; Isabelle Trop; Andre Lisbona; Frances C Wright; Rami J Younan; Louise Provencher; Erica Patocskai; Atilla Omeroglu; Andre Robidoux
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

5.  A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer.

Authors:  Robert-Jan Schipper; Martine Moossdorff; Patty J Nelemans; Grard A P Nieuwenhuijzen; Bart de Vries; Luc J A Strobbe; Rudi M H Roumen; Franchette van den Berkmortel; Vivianne C G Tjan-Heijnen; Regina G H Beets-Tan; Marc B I Lobbes; Marjolein L Smidt
Journal:  Clin Breast Cancer       Date:  2014-01-03       Impact factor: 3.225

6.  Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

Authors:  Thorsten Kuehn; Ingo Bauerfeind; Tanja Fehm; Barbara Fleige; Maik Hausschild; Gisela Helms; Annette Lebeau; Cornelia Liedtke; Gunter von Minckwitz; Valentina Nekljudova; Sabine Schmatloch; Peter Schrenk; Annette Staebler; Michael Untch
Journal:  Lancet Oncol       Date:  2013-05-15       Impact factor: 41.316

7.  Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance).

Authors:  Huong T Le-Petross; Linda M McCall; Kelly K Hunt; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Karla V Ballman; Judy C Boughey
Journal:  AJR Am J Roentgenol       Date:  2018-01-30       Impact factor: 3.959

8.  Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.

Authors:  Tina J Hieken; Judy C Boughey; Katie N Jones; Sejal S Shah; Katrina N Glazebrook
Journal:  Ann Surg Oncol       Date:  2013-07-12       Impact factor: 5.344

9.  The influence of breast cancer subtypes on axillary ultrasound accuracy: A retrospective single center analysis of 583 women.

Authors:  Ruth Helfgott; Martina Mittlböck; Maria Miesbauer; Farid Moinfar; Silke Haim; Maria Mascherbauer; Paul Schlagnitweit; Dietmar Heck; Michael Knauer; Florian Fitzal
Journal:  Eur J Surg Oncol       Date:  2018-10-10       Impact factor: 4.424

10.  Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer.

Authors:  Jee Ye Kim; Hyung Seok Park; Sanghwa Kim; Jegyu Ryu; Seho Park; Seung Il Kim
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.